Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 28 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

The capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea and chronic diarrhea associated with inflammatory bowel disease. The drug will be manufactured at the company's facility in Ahmedabad, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 28, 2023, titled "Zydus receives Final Approval from the USFDA for Loperamide Hydrochloride Capsules USP, 2 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases